This Week in Psychedelics
Apr 8, 2026
•
12 min read
[5-min read] Texas plans to move ibogaine initiative forward without a drug company.
Apr 1, 2026
13 min read
[5-min read] Otsuka agrees to acquire Transcend Therapeutics for $1.225 billion.
Mar 25, 2026
[5-min read] 24-trial review suggests psychedelics are no more effective than antidepressants.
Mar 18, 2026
[5-min read] One dose of psilocybin beats nicotine patches by a factor of six.
Mar 11, 2026
[5-min read] New study suggests psilocybin and MDMA repair myelin.
Mar 4, 2026
[5-min read] RAND report estimates 23% of U.S. adults support legalizing psilocybin.
Feb 25, 2026
[5-min read] FDA designates luvesilocin a breakthrough therapy.
Feb 18, 2026
[5-min read] Compass shares results from second Phase 3 psilocybin trial.
Feb 11, 2026
[5-min read] Pilot program brings at-home ketamine-assisted therapy to hospice patients.
Feb 4, 2026
[5-min read] Preclinical research shows low-dose psilocybin reverses metabolic disease.
Jan 28, 2026
[5-min read] RAND study projects 10 million Americans microdosed in 2025.
Jan 21, 2026
[5-min read] WHO data suggests severe adverse events from psychedelics are rare.
Jan 14, 2026
[5-min read] FDA accepts Compass Pathways' application to test psilocybin for PTSD.
Jan 7, 2026
[5-min read] Real-world psilocybin therapy study tempers expectations for treatment-resistant depression.
Dec 31, 2025
10 min read
[4-min read] 2025's biggest psychedelic shifts and our predictions for 2026.
Dec 24, 2025
[5-min read] Psychedelics stocks rally after cannabis rescheduling order.
Dec 17, 2025
11 min read
[5-min read] Psilocybin reduces symptoms of OCD in 48 hours.
Dec 10, 2025
[5-min read] Researchers conduct first trial of MDMA-assisted therapy for depression.
Dec 3, 2025
[5-min read] DEA announces steep production quota increases for multiple psychedelics.
Nov 26, 2025
[5-min read] Study finds psychedelic decriminalization hasn't increased ER visits.
Nov 19, 2025
[5-min read] AtaiBeckley posts open-label extension results for its 5-MeO-DMT formulation.
Nov 12, 2025
[5-min read] Maryland task force proposes three-phased approach to psychedelic legalization.
Nov 5, 2025
[5-min read] Arizona-funded clinical trial will test whole psilocybin mushrooms for PTSD.
Oct 29, 2025
[5-min read] Ketamine company receives one of nine FDA Commissioner's National Priority Vouchers.
Oct 22, 2025
14 min read
[5-min read] atai receives FDA's seventh breakthrough therapy designation for a psychedelic drug.
